Skip to main content

Table 2 A summary of the scores obtained by VAS questionnaire

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

  Univariable Multivariable
Mean ± SD
Median (IQR)
P-value Coefficient (95% CI) P-value
Group
 Active 3.27 ± 0.88
3 (1)
0.0001 Reference 0.0001
 Placebo 5.87 ± 1.02
6 (2)
2.58 (2.11, 3.06)
Sex
 Female 4.56 ± 1.52
5 (3)
0.771 0.09 (−0.48, 0.65) 0.761
 Male 4.48 ± 1.83
4 (3)
Reference
Marital Status
 Single 4.67 ± 1.58
4 (3)
0.582 0.25 (−0.41, 0.92) 0.452
 Married 4.45 ± 1.65
4.5 (3)
Reference
Duration of Migraine
 ≤2 years 4.58 ± 1.63
4.50 (3)
0.710 0.30 (−0.23, 0.84) 0.262
 > 2 years 4.46 ± 1.62
4 (3)
Reference
Age (rho) - 0.05 0.711 0.02 (−0.02, 0.06) 0.277
BMI (rho) - 0.06 0.648 - 0.03 (−0.14, 0.08) 0.567
Number of attack pre-treatment (rho) 0.15 0.232 0.27 (0.01, 0.54) 0.007
  1. BMI Body–mass index, SD Standard deviation, IQR Interquartile range, rho Spearman correlation coefficient